356 related articles for article (PubMed ID: 33533931)
1. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
2. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
[TBL] [Abstract][Full Text] [Related]
3. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
Olfat M; Silverman ED; Levy DM
Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
[TBL] [Abstract][Full Text] [Related]
5. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K
Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hospitalization due to infection in rituximab-treated MS patients.
Karlowicz JR; Klakegg M; Aarseth JH; Bø L; Myhr KM; Torgauten HM; Torkildsen Ø; Wergeland S
Mult Scler Relat Disord; 2023 Mar; 71():104556. PubMed ID: 36842313
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
9. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
Alexander S; Aupérin A; Bomken S; Csóka M; Kazanowska B; Chiang AK; Andres M; Uyttebroeck A; Burke GAA; Zsiros J; Pillon M; Bollard CM; Mussolin L; Verdu-Amoros J; Neven B; Barkauskas DA; Wheatley K; Patte C; Gross TG; Minard-Colin V; ;
Lancet Haematol; 2023 Jun; 10(6):e445-e457. PubMed ID: 37094596
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
[TBL] [Abstract][Full Text] [Related]
11. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections.
Langer-Gould A; Li BH; Smith JB; Xu S
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200211. PubMed ID: 38507657
[TBL] [Abstract][Full Text] [Related]
12. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.
Watson L; Beresford MW; Maynes C; Pilkington C; Marks SD; Glackin Y; Tullus K
Lupus; 2015 Jan; 24(1):10-7. PubMed ID: 25117653
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
[TBL] [Abstract][Full Text] [Related]
15. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
16. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
18. Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
Zonozi R; Wallace ZS; Laliberte K; Huizenga NR; Rosenthal JM; Rhee EP; Cortazar FB; Niles JL
Arthritis Rheumatol; 2021 Feb; 73(2):347-354. PubMed ID: 32892495
[TBL] [Abstract][Full Text] [Related]
19. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Barmettler S; Ong MS; Farmer JR; Choi H; Walter J
JAMA Netw Open; 2018 Nov; 1(7):e184169. PubMed ID: 30646343
[TBL] [Abstract][Full Text] [Related]
20. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
